Allogene Therapeutics Inc
$ 2.73
7.91%
26 Feb - close price
- Market Cap 568,567,000 USD
- Current Price $ 2.73
- High / Low $ 2.74 / 2.52
- Stock P/E N/A
- Book Value 1.41
- EPS -0.98
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.54 %
- 52 Week High 2.74
- 52 Week Low 0.86
About
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Analyst Target Price
$7.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-07 | 2024-05-13 | 2024-03-14 | 2023-11-02 | 2023-08-02 | 2023-05-03 | 2023-02-28 |
| Reported EPS | -0.19 | -0.23 | -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.43 | -0.37 | -0.53 | -0.68 | -0.66 |
| Estimated EPS | -0.22 | -0.27 | -0.41 | -0.3234 | -0.33 | -0.35 | -0.41 | -0.45 | -0.52 | -0.59 | -0.62 | -0.7 |
| Surprise | 0.03 | 0.04 | 0.13 | 0.0434 | 0.01 | 0 | 0.03 | 0.02 | 0.15 | 0.06 | -0.06 | 0.04 |
| Surprise Percentage | 13.6364% | 14.8148% | 31.7073% | 13.4199% | 3.0303% | 0% | 7.3171% | 4.4444% | 28.8462% | 10.1695% | -9.6774% | 5.7143% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALLO
2026-02-22 15:06:20
The FDA has removed the clinical hold on all five of Allogene Therapeutics' (ALLO) allogeneic CAR T ("AlloCAR T") studies, which had been in place since October 2021. The hold was lifted after investigations concluded that a reported chromosomal abnormality with unclear clinical significance was not related to Allogene's manufacturing process or gene-editing technology and had no clinical significance. This decision allows Allogene to resume clinical development for its AlloCAR T pipeline candidates.
2026-02-19 14:05:00
Allogene Therapeutics Inc. (NASDAQ: ALLO) shares fell over 7% following an earnings report that highlighted a negative revenue trajectory and significant operational hurdles. Despite strategic shifts and clinical trial progress, the company faces internal inefficiencies and intense competition within the biopharmaceutical sector.
2026-02-16 17:27:57
Allogene Therapeutics announced its participation in Citi’s 2026 Virtual Oncology Leadership Summit on February 18. The company will provide updates on its investigational allogeneic CAR T pipeline and its overall corporate strategy. A webcast will be available on Allogene's Investor Relations site for stakeholders.
2026-02-14 07:58:15
The "Follicular Lymphoma Pipeline Insight, 2025" report by DelveInsight evaluates over 45 companies developing more than 50 treatment therapies for Follicular Lymphoma, covering clinical and commercial aspects from preclinical to marketed phases. Key companies like InnoCare Pharma, AstraZeneca, and Allogene Therapeutics are advancing therapies such as ICP 248, ALLO-501, and acalabrutinib. Recent significant developments include FDA approvals for epcoritamab-bysp in combination therapies and tafasitamab-cxix, as well as EC approval for lisocabtagene maraleucel, signaling a dynamic landscape with ongoing clinical advancements.
2026-02-14 07:27:24
Wall Street Zen downgraded Allogene Therapeutics (NASDAQ:ALLO) from "hold" to "sell." Despite this, the consensus analyst rating for ALLO remains a "Moderate Buy" with an average price target of $8.40. Insider selling has been observed, with executives selling shares, while the stock currently trades around $1.80.
2026-02-12 09:27:49
Allogene Therapeutics (ALLO) has significantly outperformed the Medical sector this year, returning 23.4% compared to the sector's 0.9% average. The company holds a Zacks Rank of #2 (Buy), reflecting positive analyst sentiment and an improving earnings outlook. McKesson (MCK), another Medical stock, has also outpaced the sector with a 14% year-to-date return and a Zacks Rank #2 (Buy).
